Genmab — Februar 2021
-
Her er artikel fra Børsen med mere information: Citi om Genmab-succes i lungekræft: Kan være op mod 20 mia. kr. værd
-
Citi om Genmab-succes i lungekræft: Kan være op mod 20 mia. kr. værd
Genmab og partneren Janssen Pharmaceuticals kan have en god behandling på vej mod sjælden type af lungekræft, og Citi ser stor værdi i projektet En ny kræftbehandling, udviklet af biotekselskabet Genm
borsen.dk (borsen.dk)
-
@pensionisten - har desværre ikke link - har bladet fysisk - hvis du sender mail adresse kan jeg godt tage fotos og sende dig (kan ikke gennemskue om man kan sende fotos her)
-
Fra Euroinvestor - nu med lidt mere "kød" i artiklen
https://www.euroinvestor.dk/nyheder/derfor-ser-storbank-nyt-milliardpotentiale-i-genmab -
Aktier/tendens: Novo Nordisk og Genmab i centrum i positivt marked:https://www.proinvestor.com/investornyt/671635/aktier-tendens-novo-nordisk-og-genmab-i-centrum-i-positivt-marked
-
@pensionisten - done
-
velbekomme - ha en profitabel dag:)
-
Car-T (JNJ-68284528) efter DPd på Riget. https://haematologisktidsskrift.dk/sygdomme/myeloma/812-forste-myelomatosepatient-pa-rigshospitalet-i-forsog-med-car-t.html
-
Ovennævnte netop accepteret af ema til accelereret behandling. http://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/janssen-announces-car-t-therapy-ciltacabtagene-autoleucel-cilta
-
God morgen.
-
Asien: Optimisme og positive futures giver brede stigninger:
https://www.proinvestor.com/investornyt/671665/asien-optimisme-og-positive-futures-giver-brede-stigninger -
Tirsdagens aviser med Bavarian, TDC og Danske Bank: https://www.proinvestor.com/investornyt/671664/tirsdagens-aviser-med-bavarian-tdc-og-danske-bank
-
World Lung 2020 – amivantamab puts more data behind the hype https://www.evaluate.com/vantage/articles/events/conferences/world-lung-2020-amivantamab-puts-more-data-behind-hype
-
Horizon
on Tepezza disruption https://twitter.com/HorizonNews/status/1356386606471610368 -
ah, this may be why, 'Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401' https://www.globenewswire.com/news-release/2021/02/02/2167963/0/en/Immunovant-Announces-Voluntary-Pause-in-Clinical-Dosing-of-IMVT-1401.html#.YBk7ta8wc3k.twitter ; this is a potential Tepezza competitor
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind